Search results
Results From The WOW.Com Content Network
The structure of desmoteplase is similar to rt-PA (), but it does not contain the plasmin-sensitive cleavage site and the lysine-binding Kringle 2 domain.As a result, desmoteplase, in comparison to rt-PA, has high fibrin selectivity (100,000- v. 550-fold increase in catalytic activity), an absence of neurotoxicity, and no apparent negative effect on the blood–brain barrier.
The Copenhagen Stroke Study, which is a large important study published in 2001, showed that out of 618 stroke patients, manual apraxia was found in 7% and oral apraxia was found in 6%. [98] Both manual and oral apraxia were related to increasing severity of stroke.
3K3A-Activated Protein C (3K3A-APC) is an experimental drug for the treatment of stroke developed by ZZ Biotech. [1] It is also being assessed for the treatment of Alzheimer's disease . [ 2 ] It is the subject of RHAPSODY, a phase II trial to determine safety and tolerability.
A cerebroprotectant (formerly known as a neuroprotectant) is a drug that is intended to protect the brain after the onset of acute ischemic stroke. [1] As stroke is the second largest cause of death worldwide and a leading cause of adult disability, over 150 drugs have been tested in clinical trials to provide cerebroprotection.
However, many patients who were eligible for treatment were not treated. [14] [15] tPA has also been given to patients with acute ischemic stroke above age 90 years old. Although a small fraction of patients 90 years and above treated with tPA for acute ischemic stroke recover, most patients have a poor 30-day functional outcome or die. [16]
Berberine, a plant compound traditionally used in herbal medicine, is today commonly stocked on the shelves of health food stores and pharmacies as a supplement.. Berberine supplements gained ...
Alteplase, sold under the brand name Activase among others, is a biosynthetic form of human tissue-type plasminogen activator (t-PA). It is a thrombolytic medication used to treat acute ischemic stroke, acute ST-elevation myocardial infarction (a type of heart attack), pulmonary embolism associated with low blood pressure, and blocked central venous catheter. [5]
The Ontario Stroke Registry (formerly the Registry of the Canadian Stroke Network (RCSN)) was established in 2001 to allow for the measurement and monitoring of stroke care delivery and outcomes in Canadian patients at participating institutions, and to serve as a rich clinical database for investigator-initiated research projects.